---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-007371"
form_type: "8-K"
ticker: "PAHC"
cik: "0001069899"
company_name: "PHIBRO ANIMAL HEALTH CORP"
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T08:35:43.117846+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Phibro Animal Health Reports Q3 FY2024 Results; Updates Guidance, Plans Zoetis Acquisition

## Summary
- Net sales for Q3 ended March 31, 2024 were $263.2M, up 7% YoY; Animal Health segment grew 10%.
- Adjusted EBITDA increased 9% to $29.7M; adjusted diluted EPS rose to $0.31 from $0.29.
- Affirmed FY2024 net sales guidance of $980M-$1.02B and Adjusted EBITDA of $106M-$112M.
- Signed agreement to acquire Zoetis' Medicated Feed Additive portfolio to enhance product offerings.
- Vaccine sales surged 26% and MFA and other sales increased 16% in the quarter.

## SEC filing metadata
- accession: 0001558370-24-007371
- form_type: 8-K
- ticker: PAHC
- cik: 0001069899
- company_name: PHIBRO ANIMAL HEALTH CORP
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069899/000155837024007371/0001558370-24-007371-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069899/000155837024007371/pahc-20240508x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-007371
- JSON: https://secwatch.observer/filing/0001558370-24-007371.json
- Plain text: https://secwatch.observer/filing/0001558370-24-007371.txt

## Key facts
- Earnings Releases
  PHIBRO ANIMAL HEALTH CORP reported the fiscal quarter ended March 31, 2024 results: revenue $263.2 million, net income $8.4 million, EPS $0.21.
  - Period: the fiscal quarter ended March 31, 2024
  - Revenue: $263.2 million
  - Net income: $8.4 million
  - EPS: $0.21
  - Result: reported results
  source text: Net sales of $263.2 million, an increase of $17.6 million, or 7% - Net income of $8.4 million, a decrease of $1.6 million - Diluted earnings per share of $0.21, a decrease of $0.04
  evidence_url: https://www.sec.gov/Archives/edgar/data/1069899/000155837024007371/0001558370-24-007371-index.htm
- Earnings Releases
  PHIBRO ANIMAL HEALTH CORP reported the fiscal year ending June 30, 2024 results: revenue $980 million to $1.020 billion, net income $7 million to $12 million, EPS $0.17 to $0.30.
  - Period: the fiscal year ending June 30, 2024
  - Revenue: $980 million to $1.020 billion
  - Net income: $7 million to $12 million
  - EPS: $0.17 to $0.30
  - Result: guidance update
  source text: We affirm our previously issued fiscal year 2024 guidance for the following measures: ​ – Net sales of $980 million to $1.020 billion – Adjusted EBITDA of $106 million to $112 million – Adjusted net income of $42 million to $47 million – Adjusted diluted EPS of $1.04 to $1.16 – Adjusted effective tax rate of 28% to 30% ​ We have updated our fiscal year 2024 guidance for the following measures: ​ - Net income of $7 million to $12 million - Diluted EPS of $0.17 to $0.30
  evidence_url: https://www.sec.gov/Archives/edgar/data/1069899/000155837024007371/0001558370-24-007371-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.